Parikh K, Dimou A, Leventakos K, Mansfield AS, et al. Impact of EML4-ALK Variants and Co-Occurring TP53 Mutations on Duration of First-Line ALK Tyrosine Kinase Inhibitor Treatment and Overall Survival in ALK Fusion-Positive NSCLC: Real-World Outcomes From the GuardantINFORM database. J Thorac Oncol 2024;19:1539-1549.
PMID: 39019326